{
  "id": 11437582,
  "title": "Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases",
  "url": "https://urgent.news/2026/10/02/denmarks-breye-therapeutics-raises-67-5-million-to-advance-oral",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-02T12:20:33.000Z",
  "source": {
    "name": "EU-Startups",
    "slug": "eu-startups",
    "url": "https://www.eu-startups.com/2026/10/denmarks-breye-therapeutics-raises-e67-5-million-to-advance-oral-therapies-for-early-treatment-of-retinal-diseases/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Danish biopharmaceutical company Breye Therapeutics has secured €67.5 million in Series A funding to advance its oral therapies for early treatment of retinal diseases. The round was led by Mission BioCapital and co-led by existing investor Novo Holdings, with participation from other new investors such as the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital. The funding will enable Breye to progress its pioneering oral treatment, danegaptide, for diabetic retinopathy to the next stage of clinical development. The CEO, Ulrik Mouritzen, highlighted the financing as a major milestone, reflecting strong confidence in the company's vision and pipeline. Danegaptide is a first-in-class oral small molecule with a novel mechanism of action that stabilises retinal vasculature, offering a patient-friendly treatment option for diabetic retinopathy, which affects about 130 million people worldwide.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}